|
MK-2010 Clinical Trials
2 actively recruiting trials across 2 locations
▲ +1 trial since September 2026
Also known as: LM-299
Pipeline
Phase 2: 1Phase 1/2: 1
Top Sponsors
- Merck Sharp & Dohme LLC2
Indications
- Cancer2
- Ovarian Cancer Recurrent1
- Malignant Neoplasm1
- Advanced Solid Tumors1
New Haven, Connecticut1 trial
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)
Phase 1/2
San Antonio, Texas1 trial
A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)
START San Antonio ( Site 0220)
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.